Is Adicet Bio, Inc. (ACET) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.6% / 30% | 251.9% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 24.6% / 33% | 251.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 7.8% / 33% | 80.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 24.6% / 33% | 251.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 7.8% / 33% | 80.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -67.6% | |
| Return on Assets (ROA) | -37.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$95M |
| Free Cash Flow | -$97M |
| Total Debt | $15M |
| Debt-to-Equity | 9.3 |
| Current Ratio | 7.5 |
| Total Assets | $192M |
Price & Trading
| Last Close | $6.73 |
| 50-Day MA | $7.39 |
| 200-Day MA | $10.24 |
| Avg Volume | 172K |
| Beta | 1.6 |
|
52-Week Range
$6.41
| |
About Adicet Bio, Inc. (ACET)
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Adicet Bio, Inc. (ACET) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Adicet Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Adicet Bio, Inc.'s debt ratio?
Adicet Bio, Inc.'s debt ratio is 24.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.8%.
What are Adicet Bio, Inc.'s key financial metrics?
Adicet Bio, Inc. has a market capitalization of $62M. Return on equity stands at -67.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.